This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
Trebbastoni, A., Raccah, R., de Lena, C., Zangen, A., & Inghilleri, M. (2013). Brain stimulation, 6(4), 545-553.
This case report examines the effect of Brainsway Deep TMS (Transcranial Magnetic Stimulation) in a patient that had a language disorder involving changes in the ability to speak, read, write and understand what others are saying. The patient underwent four 20-minute stimulation cycles, including two real sessions and two sham sessions, over five consecutive days. In this patient, both the ability to speak and to write were significantly enhanced following one week of deep brain stimulation, but not following sham stimulation.